Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Operating Leases (2022 - 2025)

Rapid Micro Biosystems' Operating Leases history spans 4 years, with the latest figure at $3.7 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 25.84% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 25.84% decrease, with the full-year FY2025 number at $3.7 million, down 25.84% from a year prior.
  • Operating Leases hit $3.7 million in Q4 2025 for Rapid Micro Biosystems, down from $4.0 million in the prior quarter.
  • Over the last five years, Operating Leases for RPID hit a ceiling of $7.7 million in Q2 2022 and a floor of $1.3 million in Q1 2022.
  • Historically, Operating Leases has averaged $5.5 million across 4 years, with a median of $5.8 million in 2024.
  • Biggest five-year swings in Operating Leases: surged 433.85% in 2023 and later dropped 25.84% in 2025.
  • Tracing RPID's Operating Leases over 4 years: stood at $7.2 million in 2022, then fell by 13.72% to $6.2 million in 2023, then fell by 20.28% to $5.0 million in 2024, then dropped by 25.84% to $3.7 million in 2025.
  • Business Quant data shows Operating Leases for RPID at $3.7 million in Q4 2025, $4.0 million in Q3 2025, and $4.3 million in Q2 2025.